Neil New Pic

Neil Desai, PhD

Founder, CEO and President

Dr. Desai is the founder of Aadi and has served as Aadi’s President, Chief Executive Officer and Chairman of Aadi’s board of directors since Aadi’s founding in October 2011. He is an inventor of the nab® technology, Abraxane® and FyarroTM. From October 2010 to October 2016, Dr. Desai served as Vice President, Strategic Platforms at Celgene Corporation (now Bristol Myers Squibb), a global biopharmaceutical company. Prior to Celgene, Dr. Desai served as Senior Vice President, Global Research and Development at Abraxis BioScience, Inc., a biotechnology company, from November 2008 until Abraxis BioScience was acquired by Celgene Corporation in October 2010 and as Vice President, Research & Development at Abraxis BioScience from March 1999 to October 2008. Dr. Desai has also previously served in positions of increasing seniority at American BioScience, Inc. and its predecessor companies. He has over 25 years of experience in novel therapeutic delivery systems with numerous issued patents, peer-reviewed publications and book chapters, and presentations at scientific meetings. He participated in FDA and EU Nanotechnology initiatives and was a member of the Steering Committee for the National Cancer Institute (NCI) Alliance for Nanotechnology in Cancer.  

Dr. Desai holds a M.S and Ph.D. in Chemical Engineering from the University of Texas at Austin, and a B.S. in Chemical Engineering from the University Institute of Chemical Technology in Mumbai, India.


Brendan Delaney


Brendan Delaney brings more than 25 years of global product strategy and oncology launch experience to his role leading commercial organizations. He most recently served as the Chief Commercial Officer of Constellation Pharma which was recently acquired by MorphoSys for $1.4B. Prior to joining Constellation, Mr. Delaney was the Chief Commercial Officer at Immunomedics, where he led the buildout of the marketing, sales, market access and commercial operations teams. He was instrumental in successfully launching Trodelvy, the first TROP-2 directed antibody-drug conjugate for the treatment of triple-negative breast cancer. Immunomedics was acquired by Gilead Sciences for $21B in September 2020.  Previously, he served as Vice President of U.S. Hematology-Oncology at Celgene Corporation. Prior to joining Celgene, he held various commercial roles at both Novartis Oncology and Genentech, where he led several successful product launches for blockbuster brands. 

He earned an MBA from the Stern School of Business at NYU and a B.A. in biology from Rutgers Universit

Lance Pic

Lance Thibault

Interim CFO

Mr. Thibault has served as Interim Chief Financial Officer of Aadi since July 2021. Since January 2014, Mr. Thibault has served as managing director of Danforth Advisors, LLC providing operational, financial and strategic services at a number of private and public pharmaceutical and biotechnology companies, including from February 2017 to April 2018, Mr. Thibault served as Acting Chief Financial Officer of Pieris Pharmaceuticals, Inc (NASDAQ: PIRS), a clinical-stage biotechnology company, and from April 2015 to August 2016, Mr. Thibault’s served as Interim Chief Financial Officer of Proteostasis Therapeutics, Inc. (NASDAQ: PTI). Prior to 2010, Mr. Thibault was Chief Financial Officer and Treasurer of deCODE genetics, Inc. (NASDAQ: DCGN), and a director at PricewaterhouseCoopers LLP. Mr. Thibault is a C.P.A. and received his B.S. in Accountancy from Bentley University


Mitchall Clark, Bpharm, MRPharmS

SVP, Regulatory Affairs and Quality Assurance

Mitch was formerly Chief Regulatory /Quality, Atara Biotherapeutics; SVP Regulatory Affairs, Nantworks; and SVP Regulatory affairs at Abraxis Bioscience where he was responsible for global approvals for Abraxane® and regulatory for early stage to post-marketing of nab products. He has 30+ yrs in international regulatory affairs with Schering AG, FH Faulding/Purepac & APP/Abraxis, Clinical and Manufacturing QA, drug safety and clinical operation.


Berta Grigorian, BS

VP, Clinical Operations

Berta was former Clinical Operations Manager at Amgen and comes with 20 years industry experience spanning all phases of drug development with a focus on oncology and cardiovascular products. She has led cross functional teams to plan and execute a successful US BLA filing for an Amgen cardiovascular product; global activities for various oncology studies to ensure quality, consistency, and integration of all study data; and was responsible for global study management goals (enrollment, data flow, drug supply) for several clinical products.


Nancy Jorgesen, MS, MBA

VP, Project Leadership

Nancy was most recently VP of Project Leadership at Atara Biotherapeutics and VP of Project Management & Corporate Operations at Kythera Biopharmaceutics. She began her career at Amgen where she became Director of Global Project Management. Nancy has 25+ years of cross-functional product leadership across all stages of drug development including early research through commercialization/lifecycle management.


Andrew Kwon, PhD

Senior Director BD & Corporate Strategy

Andrew brings 13 years of biotech industry experience focused on Business Development and Commercial Strategy in oncology and spent 11 years as a strategy consultant working with top biopharma companies. He was originally trained as cancer biologist and has held positions as a Research Scientist at Memorial Sloan Kettering Cancer Center and Associate at Radius Ventures. Andrew received a B.S. in Biology from Brown University, Ph.D. in Molecular and Medical Pharmacology from University of California Los Angeles, and M.B.A. from Columbia Business School.